NCT07832513Not yet recruiting
Study of Pregnancy in Patients With Myeloproliferative Neoplasms
A Prospective Multicentre Study to Evaluate Maternal and Perinatal Outcomes in Myeloproliferative Neoplasms: MAPP-MPN Trial
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This is a study to evaluate pregnancy in patients with myeloproliferative neoplasms. The main endpoint of this study is to determine the number of live births in pregnant MPN patients who are managed by a risk-adapted algorithm
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 16 Sept 2026
- Start date
- 5 Oct 2026
- Primary completion date
- 5 Oct 2028
- Lead sponsor
- University Health Network, Toronto
- NCT number
- NCT07832513
What you commit to
- Study type: Observational
- Planned participants: 30
- From 5 Oct 2026 to the primary completion date, 5 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concurrent disease that in the opinion of the investigator may be adversely impact the safety of the patient or impair assessment of study results, including but not limited to:
- Second malignancy requiring concurrent treatment, except basal cell carcinoma or squamous cell carcinoma or cervical carcinoma in situ.
Other illness
- Patients with a diagnosis of chronic myeloid leukemia, myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or other myeloid malignancy.
- Uncontrolled autoimmune diseases (e.g., hepatitis, immune thrombocytopenic purpura \[ITP\], scleroderma, autoimmune arthritis)
- Active, uncontrolled infection (e.g., HIV, hepatitis B, hepatitis C)
Other
- Peripheral blood or marrow blasts \>/= 10%.
- Patients requiring a legally authorized representative.
Who the study is looking for
- Patients with a diagnosis of chronic phase essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic or overt primary myelofibrosis (PMF), post-ET myelofibrosis (MF), post-PV MF, or myeloproliferative neoplasm (MPN) - unclassifiable according to the 2022 International Consensus Criteria. Patients who have not had a diagnostic bone marrow biopsy may participate if there is a driver mutation and all other diagnostic criteria are met.
- Patients with a confirmed pregnancy through Beta Human Chorionic Gonadotropin (BHCG) testing of the urine or blood and/or dating ultrasound. Patients may be eligible to participate at any stage of pregnancy.
- Patients must have the ability to participate in study procedures.
- Participants must provide consent to participate in this study.
Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.